Energenesis Biomedical CO.,LTD. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 2.86 million compared to TWD 3.59 million a year ago. Net loss was TWD 100.35 million compared to TWD 53.9 million a year ago. Basic loss per share from continuing operations was TWD 1.51 compared to TWD 0.9 a year ago. Diluted loss per share was TWD 1.51 compared to TWD 0.9 a year ago.